RS
Therapeutic Areas
Character Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CTX203 | High risk intermediate AMD (dry AMD) | Phase 1 |
| CTX114 | Geographic Atrophy (secondary to AMD) | Phase 1 |
| Undisclosed AMD Program | Age-Related Macular Degeneration (AMD) | Research |
| Undisclosed POAG Program | Primary Open-Angle Glaucoma (POAG) | Research |
Leadership Team at Character Biosciences
CZ
Cheng Zhang
CEO, Co-Founder
LC
Laura Carter, PhD
Chief Scientific Officer
RK
Robert Kim, MD, MBA
Chief Medical Officer
DE
Daniel Elgort, PhD
Chief Data and Analytics Officer
EK
Erik Karrer, PhD
SVP, Drug Discovery
KS
Kaila Smilen, MBA
Senior Director, BD & Corporate Strategy
DC
Dinah Chen, MD
Medical Director and Clinical Innovation Lead
JG
Jonathan Gumucio, PhD
Director, Drug Discovery
MC
May Chen, PhD
Director, Drug Discovery
JB
Josh Buddle
Head of Clinical Network and Longitudinal Research